ArticleNeuro-oncology advances
A common signature of brain metastases among patients with breast cancer, melanoma, and lymphoma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite considerable improvement in cancer treatments, brain metastases are still challenging daily practice in oncology. Their biology remains largely unknown with limited data obtained from brain metastatic samples. Here, using metastatic samples of three different cancer types-breast cancer, melanoma and lymphoma-we aimed to identify a common genomic signature related to metastatic localizations in the brain. Methods: Using samples from 133 patients with metastatic breast cancer, melanoma, or lymphoma, laser-microdissection of cancer cells and transciptomic analyzes were performed on 29 brain metastatic samples, and compared to data from 104 extra-cerebral metastases. To obtain murine models of the common brain metastatic signature observed in patients with these three cancer types, Results: Among patients, we identified 23 common genes up-regulated in brain metastases from breast cancer, melanoma, and lymphoma, including KLK6, a serine protease with trypsin-like properties and physiological expression in oligodendrocytes and normal brain endothelial cells. At protein level, KLK6 expression was significantly higher in brain metastases than in extra-cerebral metastases. In particular, KLK6 was not overexpressed in extra-cerebral metastases of patients who developed brain metastases. In murine models of breast cancer, melanoma, and lymphoma brain metastases, we confirmed that KLK6 overexpression was linked to the implantation of cancer cells in the brain. Conclusion: KLK6 overexpression is linked to brain localizations whatever the cancer type, which provides new perspectives for the development of anti-KLK6 therapeutic strategies, pending specific cancer cell targeting to avoid cytotoxicity on normal brain cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.